Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
North Eastern German Society of Gynaecological Oncology
The aim of the study was to confirm the tolerability of 3-day topotecan therapy in combination with carboplatin in accordance with published data and to investigate the tolerability of continued therapy until disease progression or up to a maximum of 12 months.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age \>= 18 years
patient with ovarian cancer after primary therapy
bone marrow function leukocytes \>= 4,0 x 109/ l, platelets \>= 100 109/l, hemoglobin \>= 9 g/dl
renal function creatinin \<= 1,5 mg% or creatinin clearance \>= 60 ml/min
liver function bilirubin \<= 2,0 mg/dl, SGOT, SGPT and AP within 3 fold of the reference laboratory's normal range
ECOG \<= 2
Intention of regular follow-up visits for the duration of the study
written informed consent
You may not be if
any known hypersensitivity against topotecan isomerase-I-inhibitor other medication included in the study protocol
ECOG \> 2
patients with radiotherapy within the last 4 weeks
